{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:55:41Z","timestamp":1791305741143,"version":"4.3.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"DOI":"10.1007\/s40120-026-01040-9","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:26:11Z","timestamp":1791303971000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world Treatment Patterns Among Patients with Generalized Myasthenia Gravis in the United States"],"prefix":"10.1007","author":[{"given":"Kavita","family":"Grover","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cloutier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geoffroy","family":"Coteur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Porpong","family":"Boonmak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine C.","family":"El Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryia","family":"Zhdanava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabelle","family":"Tardif-Samson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-2467","authenticated-orcid":false,"given":"Kavita","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"11","key":"1040_CR1","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.3390\/jcm10112235","volume":"10","author":"L Dresser","year":"2021","unstructured":"Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia gravis: epidemiology, pathophysiology and clinical manifestations. J Clin Med. 2021;10(11):2235.","journal-title":"J Clin Med"},{"issue":"1","key":"1040_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5(1):30.","journal-title":"Nat Rev Dis Primers"},{"issue":"12","key":"1040_CR3","volume":"15","author":"AK Mishra","year":"2023","unstructured":"Mishra AK, Varma A. Myasthenia gravis: a systematic review. Cureus. 2023;15(12):e50017.","journal-title":"Cureus"},{"issue":"2","key":"1040_CR4","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1093\/qjmed\/hcn152","volume":"102","author":"A Chaudhuri","year":"2009","unstructured":"Chaudhuri A, Behan P. Myasthenic crisis. QJM. 2009;102(2):97\u2013107.","journal-title":"QJM"},{"issue":"4","key":"1040_CR5","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","volume":"87","author":"DB Sanders","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016;87(4):419\u201325.","journal-title":"Neurology"},{"issue":"3","key":"1040_CR6","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, et al. International consensus guidance for management of myasthenia gravis: 2020 Update. Neurology. 2021;96(3):114\u201322.","journal-title":"Neurology"},{"issue":"1","key":"1040_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjmed-2022-000241","volume":"2","author":"M DeHart-McCoyle","year":"2023","unstructured":"DeHart-McCoyle M, Patel S, Du X. New and emerging treatments for myasthenia gravis. BMJ Med. 2023;2(1):e000241.","journal-title":"BMJ Med"},{"issue":"10","key":"1040_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. 2015;14(10):1023\u201336.","journal-title":"Lancet Neurol"},{"issue":"4","key":"1040_CR9","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","volume":"15","author":"NJ Silvestri","year":"2014","unstructured":"Silvestri NJ, Wolfe GI. Treatment-refractory myasthenia gravis. J Clin Neuromuscul Dis. 2014;15(4):167\u201378.","journal-title":"J Clin Neuromuscul Dis"},{"issue":"2","key":"1040_CR10","first-page":"255","volume":"86","author":"J Suh","year":"2013","unstructured":"Suh J, Goldstein JM, Nowak RJ. Clinical characteristics of refractory myasthenia gravis patients. Yale J Biol Med. 2013;86(2):255\u201360.","journal-title":"Yale J Biol Med"},{"issue":"5","key":"1040_CR11","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1097\/WCO.0000000000001196","volume":"36","author":"F Vanoli","year":"2023","unstructured":"Vanoli F, Mantegazza R. Current drug treatment of myasthenia gravis. Curr Opin Neurol. 2023;36(5):410\u20135.","journal-title":"Curr Opin Neurol"},{"issue":"8","key":"1040_CR12","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon D, Bril V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs. 2022;82(8):865\u201387.","journal-title":"Drugs"},{"issue":"4","key":"1040_CR13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/mus.27791","volume":"67","author":"M Mahic","year":"2023","unstructured":"Mahic M, Bozorg A, Rudnik J, Zaremba P, Scowcroft A. Treatment patterns in myasthenia gravis: a United States health claims analysis. Muscle Nerve. 2023;67(4):297\u2013305.","journal-title":"Muscle Nerve"},{"key":"1040_CR14","unstructured":"Komodo Health. Research & Publications. https:\/\/www.komodohealth.com\/publications\/. Accessed 5 Aug, 2026"},{"key":"1040_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.809999","volume":"12","author":"G Phillips","year":"2022","unstructured":"Phillips G, Abreu C, Goyal A, Li Y, Whangbo A, Gelinas D, et al. Real-world healthcare resource utilization and cost burden assessment for adults with generalized myasthenia gravis in the United States. Front Neurol. 2022;12:809999.","journal-title":"Front Neurol"},{"issue":"7","key":"1040_CR16","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1080\/03007995.2024.2353381","volume":"40","author":"M Zhdanava","year":"2024","unstructured":"Zhdanava M, Pesa J, Boonmak P, Cai Q, Pilon D, Choudhry Z, et al. Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG-events. Curr Med Res Opin. 2024;40(7):1145\u201353.","journal-title":"Curr Med Res Opin"},{"key":"1040_CR17","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. (DSM-5): American Psychiatric Publishing; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"11","key":"1040_CR18","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","volume":"43","author":"H Quan","year":"2005","unstructured":"Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43(11):1130\u20139.","journal-title":"Med Care"},{"issue":"4","key":"1040_CR19","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s40120-022-00383-3","volume":"11","author":"M Mahic","year":"2022","unstructured":"Mahic M, Bozorg AM, DeCourcy JJ, Golden KJ, Gibson GA, Taylor CF, et al. Physician-reported perspectives on myasthenia gravis in the United States: a real-world survey. Neurol Ther. 2022;11(4):1535\u201351.","journal-title":"Neurol Ther"},{"key":"1040_CR20","doi-asserted-by":"publisher","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan A, Della Marina A, Hagenacker T, Hekmat K, et al. Guideline for the management of myasthenic syndromes. Ther Adv Neurol Disord. 2023;16:17562864231213240.","journal-title":"Ther Adv Neurol Disord"},{"key":"1040_CR21","unstructured":"Institute for Clinical and Economic Review (ICER). Eculizumab and efgartigimod for the treatment of myasthenia gravis: Final policy recommendations. New England Comparative Effectiveness Public Advisory Council (NE-CEPAC); 2021."},{"issue":"3","key":"1040_CR22","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/mus.28328","volume":"71","author":"C Bacher","year":"2025","unstructured":"Bacher C, Narayanswami P, Bromberg M, Buttgereit F, Dodig D, Flanagan EP, et al. International consensus guidance for the management of glucocorticoid related complications in neuromuscular disease. Muscle Nerve. 2025;71(3):309\u201316.","journal-title":"Muscle Nerve"},{"issue":"2","key":"1040_CR23","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.nmd.2019.12.003","volume":"30","author":"MR Tannemaat","year":"2020","unstructured":"Tannemaat MR, Verschuuren JJGM. Emerging therapies for autoimmune myasthenia gravis: towards treatment without corticosteroids. Neuromuscul Disord. 2020;30(2):111\u20139.","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"1040_CR24","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2023-0108","volume":"13","author":"J Pisc","year":"2024","unstructured":"Pisc J, Ting A, Skornicki M, Sinno O, Lee E. Healthcare resource utilization, costs and treatment associated with myasthenia gravis exacerbations among patients with myasthenia gravis in the USA: A retrospective analysis of claims data. J Comp Eff Res. 2024;13(1):e230108.","journal-title":"J Comp Eff Res"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01040-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-01040-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-01040-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:26:16Z","timestamp":1791303976000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-01040-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":24,"alternative-id":["1040"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-01040-9","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"10 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kavita Grover has received personal compensation for serving as a consultant for Johnson & Johnson, Amgen, Argenx, Catalyst, Kyverna, and UCB. Martin Cloutier, Porpong Boonmak, Maryia Zhdanava, Anabelle Tardif-Samson, and Yuxi Wang are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Johnson & Johnson, which funded the development and conduct of this study and manuscript. Geoffroy Coteur is an employee of iPATH Solutions, a consulting company that has provided paid consulting services to Johnson & Johnson. Kavita Gandhi is an employee and may hold stocks for Johnson & Johnson. Antoine C El Khoury was an employee of Johnson & Johnson, Raritan, NJ, USA, at the time when the study was conducted\u00a0and may hold stock\/stock options of Johnson & Johnson.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki of 1964 and its later amendments. The study was considered exempt research under 45 CFR \u00a7 46.104(d)(4) as it involved only the secondary use of data that were de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA), specifically, 45 CFR \u00a7 164.514. Patient privacy was maintained throughout the study, and all applicable HIPAA requirements for the management of de-identified data were strictly followed. Informed consent to participate was not required because this study used only de-identified secondary data. Consent for publication was also not required because no identifiable patient information is presented.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}